The expansion of the phase 3 trial into non-infectious uveitis (NIU) was one of the reasons I decided to take a position. While there are only around 7,500 Behcet's pts in the US, NIU is a much larger opportunity - around 150,000 pts.
Actualy Uveitis is only a small portion of potential indications for the Il-1 drug Gevokizumab if it works out. Gouche being another and the CV aspect etc. In their presentations Xoma had a huge amount of slides on all the different possible indications for a succesfull Il-1 drug. It is true however that currently only Uveitis looks realistic
Market Data 
Markets 
AI
